Search results
Showing 3301 to 3315 of 8933 results
Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last updated April...
Home Get involved Our committees NICE committee meetings...
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Biographies and registered interests for members of the Technology Appraisal Committee A
Read biographies of the members of our quality standards advisory committee.
More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.
More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.
Details and meeting dates of the antimicrobials evaluation panel
Biographies and registered interests for members of the Technology Appraisal Committee C
Find out more about NICE technology appraisals advisory committee D members
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.